// App-Quantinova.ai

SAT0421 : GUSELKUMAB DEMONSTRATED AN INDEPENDENT TREATMENT EFFECT ON FATIGUE AFTER ADJUSTMENT FOR CLINICAL RESPONSE (ACR20) IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM PHASE-3 TRIALS DISCOVER 1 & 2

Researchers

Presenter

  • P. Helliwell

Principal Investigators

  • P. Rahman

  • A. Deodhar

  • A. Kollmeier

  • E. C. Hsia

  • B. Zhou

  • X. Lin

  • C. Han

  • P. J. Mease

Medical Centers

  • University of Leeds, Leeds, United Kingdom

  • Memorial University of Newfoundland, St. John's, NF, Canada

  • Oregon Health & Science Univ, Portland, United States

  • Janssen Research & Development, Raritan, United States of America

  • Perelman School of Medicine, Philadelphia, United States of America

Locations

  • United Kingdom

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Janssen and Novartis

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved